Trodelvy data presented at ESMO 2021

17 September 2021

Californian antiviral specialist Gilead Sciences (Nasdaq: GILD) has announced new data from the Phase III ASCENT study of its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy).

Presented at the European Society of Medical Oncology’s (ESMO) annual congress, the results show the impact of the ADC as a third-line option for people with metastatic triple-negative breast cancer (TNBC).

TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK